Generation of circulating tumor cell derived organoidsthrough enrichment by leukapheresis - A novel drug screening system in metastatic prostate cancer
Completed
- Conditions
- Prostate cancerCRPCHSPCMetastatic prostate cancer
- Registration Number
- NL-OMON29626
- Lead Sponsor
- Eramus Medical Center Rotterdam
- Brief Summary
https://pubmed.ncbi.nlm.nih.gov/33932725/
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 46
Inclusion Criteria
Metastatic prostate cancer.
- Intention to start (new) line of systemic treatment.
Exclusion Criteria
- Low CTC count.
- Patients with a known hypersensitivity to the used LA-anticoagulant (ACD).
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of successfully cultured organoids from CTCs obtained by LA.
- Secondary Outcome Measures
Name Time Method The collection efficiency of CTCs by LA.